The early, but encouraging data presented here indicate that PSMA-based radioligand therapy (RLT) approach could be an attractive therapy option for advanced metastatic prostate cancer patients who are not suitable candidates for conventional therapies with chemotherapy, especially due to toxicities associated with chemotherapeutic agents [9]. The gene discussed is FOLH1; the disease is metastatic prostate carcinoma.